Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;39(4):e347-e349.
doi: 10.1111/jdv.20336. Epub 2024 Sep 12.

Concurrent intrathecal nivolumab and targeted therapy in a patient with melanoma-associated leptomeningeal disease

Emma Chevallier  1 , Violaine Flory  2 , Madleen Chassang  2 , Emma Huard  1 , Fanny Burel-Vandenbos  3 , Thierry Passeron  1 , Henri Montaudié  1
Affiliations

Concurrent intrathecal nivolumab and targeted therapy in a patient with melanoma-associated leptomeningeal disease

Emma Chevallier et al. J Eur Acad Dermatol Venereol. 2025 Apr.
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

References

REFERENCES

    1. Wolchok JD, Chiarion‐Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long‐term outcomes with Nivolumab plus Ipilimumab or Nivolumab alone versus Ipilimumab in patients with advanced melanoma. J Clin Oncol. 2022;40(2):127–137.
    1. Tawbi HA, Forsyth PA, Hodi FS, Algazi AL, Hamid O, Lao CD, et al. Long‐term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open‐label, multicentre, phase 2 study. Lancet Oncol. 2021;22(12):1692–1704.
    1. Ferguson SD, Bindal S, Bassett RL, Haydu LE, McCutcheon IE, Heimberger AB, et al. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neuro‐Oncol. 2019;142:499–509.
    1. Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, et al. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023;29:898–905.
    1. Glitza IC, Rohlfs M, Guha‐Thakurta N, Basset RL, Bernatchez C, Diab A, et al. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin‐2. ESMO Open. 2018;3(1):e000283.

LinkOut - more resources